| Position | Action |
|---|---|
| Residual position (60–75% of original after trim) | 25–33% of residual allocated to $400/$365 put spread hedge (60–90 DTE) to neutralize Q3 2026 binary catalyst |
| Hot August 13 CPI print | Patient trim pacing; smaller initial tranche; wait for upper end of $413–$420 resistance zone |
| Cool August 13 CPI print | Accelerated trim; larger initial tranche at $413; compresses defensive premium |
| Close below $397 | Stop on residual position |
| Close below $385 on volume | Hard exit of residual |
UNH at $407 is a gift, not a warning — the pullback is a routine consolidation within an intact uptrend, the earnings trough has passed with Q1 2026 already normalized, and the macro environment is actively funneling capital into defensive compounders like UNH.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $342.90 | bullish |
| close_50_sma | $412.26 | bearish |
| close_10_ema | $413.44 | bearish |
| rsi | 44.10 | neutral |
| macd | -1.52 | bearish |
| macd_signal | 1.53 | — |
| macd_histogram | -3.04 | bearish |
| bollinger_lower_band | $403.48 | — |
| bollinger_mid_band | $420.27 | — |
| atr | 12.07 | — |
| current_close | $407.08 | — |
| price_vs_200_sma | +18.7% | bullish |
| price_vs_50_sma | -1.3% | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Trim 30–40% into $413–$420 resistance; reduce target weight to 1.5–2.0%; retain hedged residual as defensive compounder; stop at $397
Underweight UNH. Trim 30–40% into $413–$420 resistance zone (50-SMA/10-EMA confluence), reduce target weight to 1.5–2.0% of equity portfolio, retain smaller hedged core position. Mandatory $400/$365 put spread hedge (60–90 DTE, 25–33% of residual) required per prior lesson pattern — hedge is price of admission, not optional. Stop on residual at $397 close; hard exit below $385 on volume. Price target $400. Do not initiate new capital. Trim pacing calibrated to August 13 CPI print.
When: Price closes below $397
Then: Stop on residual
Forward P/E of 18.14x is reasonable, not expensive, given earnings recovery and FCF power
↩ rebuts: “Bear's valuation premium argument using trailing optics”
· concedes: Technical indicators show real weakness (MACD bearish cross, RSI at 44.10, trading below 10-EMA and 50-SMA); Q4 2025 was a genuine trough with operating income collapsing to $380M; The bear's technical analysis is accurate for short-term momentum
UNH at $407 prices in near-perfect earnings normalization but faces structural risks including negative tangible book value, $50B net debt, sector-wide PBM headwinds where UNH has the largest exposure, and backward-looking institutional flows—making the risk/reward asymmetric to sellers at current levels.
· concedes: The 200-SMA at $342.90 is meaningfully below current price—truly catastrophic decline would be required to reach it on fundamentals; TTM FCF of $22.8B is a real number and represents genuine cash generation; Q1 EPS did technically increase from $6.85 to $6.90 (marginal as it is); Institutional ownership by quality funds (Janus Henderson, Baron) does indicate some professional conviction; The trough may be behind us—but the recovery isn't proven
→ vs neutral: Waiting for confirmation preserves downside while forfeiting upside at exactly the wrong point in the cycle; the medium-term floor at the 50 SMA has already cracked, making this analysis paralysis rather than prudent risk management
| price_vs_10_ema |
| -1.5% |
| bearish |
| 52_week_high | $436.35 | — |
Support: 403.48 · 400 · 388 · 395 · 342.9 | Resistance: 413.44 · 412.26 · 420.27 · 437.06
UNH is undergoing a short-term pullback with price declining $29.27 (-6.7%) from the July 21 high of $436.35 to close at $407.08. The stock has broken below both its 10-EMA ($413.44) and 50-SMA ($412.26), confirming a medium-term trend break, while the 200-SMA at $342.90 remains firmly below price (+18.7%), preserving the long-term uptrend. Momentum has turned decisively bearish with MACD crossing below its signal line (MACD -1.52 vs signal 1.53) and histogram at -3.04 (deepest negative reading since late May), though RSI at 44.10 is weak but not yet oversold. ATR has expanded to 12.07 (+20% from early July), indicating elevated volatility requiring wider stop placements. Key support lies at $403.48 (Bollinger lower band), $400 (psychological), and the $388-$395 prior consolidation zone, with the 200-SMA at $342.90 as the major trend invalidation level.
Market Cap
$369.7B
Beta
0.632
Current Price (Implied)
~$407.30
52-Week High
$461.62
52-Week Low
$244.37
50-Day MA
$410.81
200-Day MA
$344.97
P/E (TTM)
30.63
Forward P/E
18.14
PEG Ratio
1.24
Price/Book
3.53
Dividend Yield
2.30%
Revenue (TTM)
$450.1B
EBITDA (TTM)
$24.3B
Net Income (TTM)
$14.1B
Profit Margin
3.14%
Operating Margin
7.13%
ROE
14.15%
ROA
4.38%
TTM EPS
$13.29
Forward EPS
$22.44
Q1 2026 EPS
$6.90
Total Assets
$312.6B
Total Equity
$105.3B
Stockholders' Equity
$97.9B
Total Debt
$77.9B
Net Debt
$49.9B
Cash & Equivalents
$28.0B
Current Ratio
0.78
Working Capital
-$23.0B
FCF (TTM)
$22.8B
Q1 2026 FCF
$8.15B
CapEx (Q1 2026)
$0.76B
Annual Dividend Run-rate
$8.0B
Shares Outstanding
907.7M
Goodwill + Intangibles
$130.6B
Tangible Book Value
-$32.7B
Long-Term Debt
$71.4B
Short-Term Debt
$6.5B
Debt/Equity
69.2
Gross Profit (TTM)
$87.84B
Q1 2026 Revenue
$111.72B
Q1 2026 Revenue YoY
+1.95%
Q1 2026 Operating Income
$8.99B
Q1 2026 Net Income
$6.28B
Q4 2025 Operating Income
$0.38B
Strengths
Concerns
UNH is in a recovery phase after a difficult 2025 that included elevated medical costs, regulatory headwinds, and the Change Healthcare cyberattack impact. Q1 2026 results are encouraging — operating income and EPS returned to year-ago levels, and free cash flow surged to $8.15B. The forward P/E of 18.1x is reasonable for an insurer with normalized earnings, especially given the low beta and cash flow profile. The stock is consolidating near the 50-day MA ($410.81), close to the 52-week high ($461.62), suggesting the recovery is well underway. Fundamental stance: HOLD with slight BUY bias on dips.